{
    "clinical_study": {
        "@rank": "141122", 
        "arm_group": {
            "arm_group_label": "S-1 + Paclitaxel Chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.\nPaclitaxel: 150 mg/m2, iv, 3h, at D1"
        }, 
        "brief_summary": {
            "textblock": "Exploratory the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the\n      Patients with Unresectable Gastric Cancer"
        }, 
        "brief_title": "Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Surgically-Created Resection Cavity", 
            "Drug Safety"
        ], 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "To assess the effectiveness and safety of S-1 + Paclitaxel for the peri-operative\n      chemotherapy in Chinese patients with unresectable gastric cancer, so as to further find out\n      the optimal protocol for the peri-operative chemotherapy in the patients with gastric\n      cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Unresectable gastric cancer as proven histologically (AJCC, Version 7) under any\n        following condition: Unable radical excision due to the local metastasis or invasion\n        Metastasis to the lymph node beside the abdominal aorta Non-extensive metastasis to liver\n        (not more than three metastatic foci of radical excision)\n\n          -  Definitely diagnosed as above stage of stomach cancer before the operation via CT or\n             MRI, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if\n             necessary\n\n          -  Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)\n\n          -  ECOG (Eastern Cooperative Oncology Group) : 0~2\n\n          -  Age: 18~75 years old\n\n          -  Normal hemodynamic indices before the recruitment (including blood cell count and\n             liver/kidney function). For example: WBC>4.0\u00d7109/L, NEU >1.5\u00d7109/L, PLT>100\u00d7109/L,\n             BIL<1.5 times of upper limit of normal reference value, ALT and AST<2.5 times of\n             upper limit of normal reference value, and CRE<1.2mg/dl\n\n          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in\n             past half year, and controllable hypertension and other coronary heart diseases\n\n          -  Not concomitant with other uncontrollable benign diseases before the recruitment\n             (e.g. the infection in the lung, kidney and liver)\n\n          -  Not participating in other study projects before and during the treatment\n\n          -  Signed the Informed Consent Form\n\n        Exclusion Criteria:\n\n          -  Not conforming to above inclusion criteria\n\n          -  Distal metastasis to lung, brain and bone (except the liver)\n\n          -  Ever operation on the stomach\n\n          -  Operation intolerance due to other systemic basic diseases\n\n          -  Ever administered other drugs (including TCM drugs) before the recruitment, or no\n             guarantee of progress according to the study requirement after the recruitment\n\n          -  Allergy to the drugs in this protocol\n\n          -  Pregnant or lactating women\n\n          -  Women at childbearing age and of pregnancy desire during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756183", 
            "org_study_id": "SPECIAL"
        }, 
        "intervention": {
            "arm_group_label": "S-1 + Paclitaxel Chemotherapy", 
            "description": "Dose of S-1: 60mg bid\uff0cTwice daily (after the breakfast and supper) for two weeks, and then suspend for one week.\nDose of Paclitaxel: 150 mg/m2, iv, 3h, at D1", 
            "intervention_name": "S-1 + Paclitaxel Chemotherapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2012", 
        "location": {
            "contact": {
                "email": "abdsurg@hotmail.com", 
                "last_name": "xiangdong Cheng, MD", 
                "phone": "+86 571 88122516", 
                "phone_ext": "-"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "xiangdong Cheng, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer", 
        "overall_contact": {
            "email": "abdsurg@hotmail.com", 
            "last_name": "xiangdong Cheng, MD", 
            "phone": "+86 571 88122516"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "xiangdong Cheng, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "radical resection rate", 
            "measure": "radical resection rate", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756183"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number and degree of Adverse Events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "the reaction rate of chemotherapy", 
                "measure": "reaction rate", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "the overall survival time", 
                "measure": "overall survival time", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}